Qiagen has been granted a patent for a kit that can assess the degradation and integrity of nucleic acids in a sample. The kit includes a primer and at least two probes that bind to specific sequences, allowing for the amplification and detection of overlapping regions within the nucleic acids. GlobalData’s report on Qiagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Qiagen, Nucleoside chemical synthesis was a key innovation area identified from patents. Qiagen's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
A kit for assessing nucleic acid degradation/integrity in samples
A recently granted patent (Publication Number: US11767553B2) describes a kit designed for assessing the status of nucleic acid degradation and/or the integrity of nucleic acids in a sample. The kit includes a primer and at least two probes that bind to specific sequences within the nucleic acids.
The first claim of the patent outlines the components of the kit. It specifies that the kit includes a primer and at least two probes. These probes are capable of binding to sequences that share at least 80% sequence identity with specific sequences listed in the patent. One of the probes binds to an overlapping region within the nucleic acids, while the other probe binds to a non-overlapping region.
The second claim further specifies that the primer and probes in the kit bind to sequences listed in the patent or their reverse complements. This indicates that the kit is designed to target specific sequences within the nucleic acids for assessment.
The third claim highlights that the sequences of the probes in the kit differ by no more than 5 nucleotides over a stretch of 20 nucleotides from specific sequences listed in the patent. This suggests that the probes are designed to closely match the target sequences, allowing for accurate detection and assessment.
Lastly, the fourth claim states that the primer in the kit has a sequence that differs by no more than 5 nucleotides over a stretch of 20 nucleotides from specific sequences listed in the patent. This indicates that the primer is also designed to closely match the target sequences, ensuring efficient amplification and detection.
Overall, this granted patent describes a kit that can be used to assess the status of nucleic acid degradation and/or the integrity of nucleic acids in a sample. The kit includes a primer and probes that bind to specific sequences within the nucleic acids, allowing for the amplification and detection of overlapping regions. The closely matched sequences of the primer and probes ensure accurate assessment and detection.
To know more about GlobalData’s detailed insights on Qiagen, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
